Navigation Links
Neurologix Reports Third Quarter 2010 Financial Results
Date:11/12/2010

FORT LEE, N.J., Nov. 12, 2010 /PRNewswire-FirstCall/ -- Neurologix, Inc. (OTC Bulletin Board: NRGX) (the "Company"), a biotechnology company developing innovative gene therapies for the brain and central nervous system ("CNS"), today reported its financial results for the three and nine months ended September 30, 2010.

"We are excited about the proven potential of NLX-P101, our Parkinson's disease gene therapy product, and continue to move forward with further definitive development," said Clark A. Johnson, President and Chief Executive Officer of the Company.  "Additionally, landmark research recently published in the journal Science Translational Medicine utilized our exclusively licensed gene therapy approach to demonstrate the importance of the p11 gene in modulating depression in mice, reversing depressive behavior of animals lacking the p11 gene.  We are extremely excited by these results, which support expanded possibilities for the development of p11 gene therapy for therapeutic use, and consider them a testament to the future commercial success of our gene therapy platform in diseases of the brain."

For the three months ended September 30, 2010, the Company reported a net loss of $2.3 million, as compared with a net loss of $3.5 million for the three months ended September 30, 2009.  Net loss for the third quarter of 2010 includes charges for the change in estimated fair value of derivative financial instruments related to warrants previously issued in connection with the Company's Series C Convertible Preferred Stock (the "Series C Stock") and the Company's Series D Convertible Preferred Stock (the "Series D Stock") of $0.3 million.  Net loss for the third quarter of 2009 includes income for the change in estimated fair value of derivative financial instruments related to warrants previously issued in connection with the Seri
'/>"/>

SOURCE Neurologix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. New Details Presented at the World Parkinson Congress on Neurologixs Successful Phase 2 Trial of Gene Therapy for Parkinsons Disease
2. Research Published in Science Translational Medicine Underscores Value of Depression Gene Therapy License Held by Neurologix
3. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
4. Spherix Reports Second Quarter Earnings
5. Tapestry Reports Second Quarter 2007 Results
6. Callisto Reports on Second-Quarter 2007 Milestones
7. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
8. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
9. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
10. TAXUS WOMAN Study Reports Positive Clinical Outcomes for the TAXUS(R) Drug-eluting Stent in Women
11. Biopure Reports on Meeting with the FDA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/10/2013)... , Dec. 10, 2013  AdCare Health Systems, ... leading long-term care provider , today announced that it ... System to manage its Crestview Health and Rehabilitation Center, ... and is located just south of downtown ... support services to Crestview including a licensed nursing home ...
(Date:12/10/2013)... Calif. , Dec. 10, 2013 ... today announced that PRIME, its phase II clinical ... quinidine) for the treatment of central neuropathic pain ... the primary efficacy endpoint. (Logo: ... PRIME study, AVP-923 treated patients experienced levels of ...
(Date:12/10/2013)... 10, 2013 In a position paper ... problem" of prescription drug abuse, the nation,s largest ... required to check state prescription drug databases before ... being circulated in California ... mandate that physicians check an electronic database of ...
Breaking Medicine Technology:AdCare Health Systems Announces New Management Agreement with Grady Health System 2AdCare Health Systems Announces New Management Agreement with Grady Health System 3Avanir Pharmaceuticals Announces Results for Phase II PRIME Study 2Avanir Pharmaceuticals Announces Results for Phase II PRIME Study 3Avanir Pharmaceuticals Announces Results for Phase II PRIME Study 4Nation's Largest Medical Society Says Doctors Should Check Drug Database Before Prescribing Addictive Drugs, Says Consumer Watchdog Campaign 2
... LONDON , March 17, 2010 Hikma Pharmaceuticals,today announced 2009 preliminary results with operating profits up 36% on the,back of a strong performance from ... ... ... ...
... Watson Pharmaceuticals, Inc. (NYSE: WPI ), a leading specialty pharmaceutical company, announced today that ... Company,s business at the Barclay,s 2010 Global Healthcare Conference on Tuesday, March 23, 2010 at ... ... ...
Cached Medicine Technology:Hikma 2009 Results Interviews With CEO and CFO 2Watson to Present at Barclay's 2010 Global Healthcare Conference 2Watson to Present at Barclay's 2010 Global Healthcare Conference 3
(Date:12/10/2013)... Peter Becker Community, a non-profit continuing care retirement ... the area’s leading home care provider, in a move ... community members. , At Peter Becker Community, ... care, which include residential living, personal care and skilled ... most seniors, however, is to stay where they currently ...
(Date:12/10/2013)... Drugmaker Merck announced on Dec. 9 that it ... Fosamax lawsuits stemming from claims that the osteoporosis drug ... Reuters. The Rottenstein Law Group LLP notes that the settlement ... , In order for the settlement to succeed, it requires ... to a Dec. 9 Reuters story.* The deadline to signal ...
(Date:12/10/2013)... December 10, 2013 Dr. Kanani, a ... his revolutionary technique of inserting dental implants. , ... dental implants has encouraged him to engineer a method that ... $4,000. Not only that, his patients undergo less pain and ... conventional method. According to Dr. Kanani, the only way for ...
(Date:12/10/2013)... The chances that wearing latex gloves will cause ... sure the skin on their hands is healthy and moist ... and skin researcher Sharon Kleyne is good news for the ... in the work place or who choose to wear them ... is Founder of Bio Logic Aqua Research, a research, education, ...
(Date:12/10/2013)... Washington, DC (PRWEB) December 10, 2013 ... stake, Medicare Advantage and Part D plans must ... ratings quality measures. On Jan. 29, some of ... executives and top industry consultants, will lead the ... publisher Atlantic Information Services, Inc. (AIS), New ...
Breaking Medicine News(10 mins):Health News:Peter Becker Community Partners with Home Helpers of Lansdale to Offer Home Care to Residents 2Health News:Peter Becker Community Partners with Home Helpers of Lansdale to Offer Home Care to Residents 3Health News:Fosamax Lawsuits Update: Rottenstein Law Group LLP Comments on Reported $28 Million Merck ‘Jaw Death’ Settlement 2Health News:Renown Woodland Hills Dentist Unveils His Revolutionary Technique of Inserting Dental Implants 2Health News:Renown Woodland Hills Dentist Unveils His Revolutionary Technique of Inserting Dental Implants 3Health News:Dry Skin a Cause of Allergy to Latex Gloves Reports Water and Skin Researcher 2Health News:Dry Skin a Cause of Allergy to Latex Gloves Reports Water and Skin Researcher 3Health News:Upcoming AIS Virtual Conference to Provide Guidance on Maximizing Medicare Star Ratings 2
... M.D., CLEVELAND, Feb. 15 Epilepsy doesn,t have ... for anyone who has epilepsy or a loved,one with ... [Cleveland Clinic Press] is an,enlightening consumer health book ... seizures and their lives., Written by Dr. Elaine ...
... on Removing,Unnecessary Toxins From Vaccines and Providing Medical ... The American Academy of,Pediatrics (AAP) has initiated ... surrounding toxins in vaccines, requesting parent,vaccine proponents to ... to media stories regarding autism and vaccines.", ...
... A Monthly Publication of the National Council on Disability ... NCD Celebrating 30 Years of Empowerment: 1978-2008, WASHINGTON, ... Disability,s monthly bulletin for January 2008:, The Bulletin, ... Web,site (http://www.ncd.gov ), brings you the latest issues ...
... N.J., Feb. 15 Novo Nordisk A/S has,filed its ... year 2007 with,the US Securities and Exchange Commission (SEC), ... The reports are available at the,SEC,s website, http://www.sec.gov, ... Shareholders and ADR holders may receive a hard ...
... has come for breast cancer risk assessment, counseling and ... realm of primary care, according to a presentation at ... , "A growing body of evidence has documented the ... with mutations in the BRCA1 and BRCA2 genes," said ...
... although essential for human life, can turn into an ... inside our cells. This "oxidative stress" is associated with ... and has been suggested to be the culprit underlying ... in the journal Proceedings of the National Academy of ...
Cached Medicine News:Health News:Cleveland Clinic Press Consumer Health Book Empowers and Gives Hope to People with Epilepsy 2Health News:AAP Initiates Public Relations Effort to Counter Bad Vaccine Publicity 2Health News:National Council on Disability Bulletin, January 2008 2Health News:National Council on Disability Bulletin, January 2008 3Health News:National Council on Disability Bulletin, January 2008 4Health News:National Council on Disability Bulletin, January 2008 5Health News:National Council on Disability Bulletin, January 2008 6Health News:Personalized medicine can cut breast cancer risk 2
... known as BMP-7, is a member of a ... Morphogenetic Proteins. OP-1 Implant is known to induce ... skeletal systems. The FDA approved OP-1 Implant under ... OP-1 Implant is now available across the country ...
Puros allografts is a family of bone products specially designed and processed to meet the demanding needs of spine surgeons. The grafts are processed using the proprietary Tutoplast process....
Lorenz 2.0 mm titanium system for the midface provides an excellent alternative to lower profile systems in areas of the midface where greater fixation is needed....
Lorenz 2.0 mm titanium system for the midface provides an excellent alternative to lower profile systems in areas of the midface where greater fixation is needed....
Medicine Products: